Get the Stockscreener App
42.44
4.25%
1.73
After Hours:
42.44
Cg Oncology Inc stock is traded at $42.44, with a volume of 708.68K.
It is up +4.25% in the last 24 hours and down -1.44% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$40.71
Open:
$40.26
24h Volume:
708.68K
Relative Volume:
0.72
Market Cap:
$3.42B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-33.41
EPS:
-1.2702
Net Cash Flow:
$-69.06M
1W Performance:
+3.49%
1M Performance:
-1.44%
6M Performance:
+61.86%
1Y Performance:
+31.23%
1-Day Range:
$40.06
$42.55
1-Week Range:
$39.20
$44.56
52-Week Range:
$14.80
$45.56
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
42.44 | 3.28B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
FY2026 EPS Estimates for CG Oncology Increased by Analyst - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Will CG Oncology Inc. stock deliver strong dividend growthJuly 2025 Chart Watch & Weekly Watchlist for Hot Stocks - newser.com
How CG Oncology Inc. stock reacts to inflationary pressuresWeekly Loss Report & Accurate Technical Buy Alerts - newser.com
CG Oncology (NASDAQ:CGON) Director Sells $41,430.00 in Stock - MarketBeat
Price action breakdown for CG Oncology Inc.2025 Technical Patterns & Risk Controlled Daily Trade Plans - newser.com
CG Oncology Inc. stock outlook for YEARPortfolio Return Report & Weekly Market Pulse Updates - newser.com
CG Oncology, Inc. Stocks Surge Amid Positive Developments - TipRanks
Midday Stock Roundup: Eledon Falls after Trial Report - Orange County Business Journal
CG Oncology, Inc. $CGON Holdings Decreased by Los Angeles Capital Management LLC - MarketBeat
New CEOs for AdvanCell, Sonoma - BioCentury
RBC Capital Maintains CG Oncology (CGON) Outperform Recommendation - Nasdaq
CG Oncology stock rises as RBC Capital raises price target on BLA filing progress - Investing.com Canada
Centessa Pharmaceuticals, CG Oncology Drive Q3 Biotech Momentum, Morgan Stanley Says - MarketScreener
CG Oncology price target raised to $61 from $53 at RBC Capital - TipRanks
Morgan Stanley Raises Price Target to CG Oncology to $82 From $79, Keeps Overweight Rating - MarketScreener
CG Oncology Plans To Complete BLA Submission For Cretostimogene In Bladder Cancer In 2026 - Nasdaq
CG Oncology, Inc.: Promising Future with Creto’s Accelerated Approval Path and Market Differentiation - TipRanks
CG Oncology (NASDAQ:CGON) Releases Earnings Results, Meets Expectations - MarketBeat
How moving averages guide CG Oncology Inc. tradingJuly 2025 Levels & Daily Oversold Bounce Ideas - newser.com
What the charts say about CG Oncology Inc. today2025 Buyback Activity & Free Long-Term Investment Growth Plans - newser.com
Why retail investors favor CG Oncology Inc. stockQuarterly Portfolio Review & Risk Controlled Daily Plans - newser.com
CG Oncology Inc Stock Analysis and ForecastSwing Trading Ideas & Low Risk Wealth Building - earlytimes.in
Will CG Oncology Inc. stock recover faster than market2025 Trading Volume Trends & Expert Curated Trade Setup Alerts - newser.com
What CG Oncology (CGON)'s FDA BLA Submission and Phase 3 Progress Mean for Shareholders - Yahoo Finance
CG Oncology (NASDAQ:CGON) Trading 6.3% HigherWhat's Next? - MarketBeat
Strategic Advancements and Risk Mitigation Drive Buy Rating for CG Oncology, Inc. - TipRanks
CG Oncology’s Impressive Q3 Revenue Surpass Amplifies Investor Interest - timothysykes.com
Sentiment analysis tools applied to CG Oncology Inc.Bond Market & AI Forecasted Entry and Exit Points - newser.com
Why CG Oncology Inc. stock attracts global investorsJuly 2025 Macro Moves & Long-Term Growth Stock Strategies - newser.com
Candriam S.C.A. Takes Position in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates - sharewise.com
CG Oncology announces 7.3M share offering - MSN
Decoding CG Oncology Inc (CGON): A Strategic SWOT Insight - GuruFocus
CG Oncology Advances Bladder Cancer Therapy Development - TipRanks
Wellington Management Group LLP Increases Stake in CG Oncology I - GuruFocus
Market reaction to CG Oncology Inc.’s recent newsMarket Growth Report & Reliable Price Breakout Alerts - newser.com
CG Oncology’s Promising Developments and Competitive Edge Drive Buy Rating - TipRanks
CG Oncology Appoints Jim DeTore as Interim CFO - TipRanks
Robert Lapetina resigned as CG Oncology's interim financial officer on Nov 10SEC filing - MarketScreener
CG Oncology, Inc. Announces Principal Financial and Accounting Officer Changes - MarketScreener
CG Oncology expects cash to fund operations into 1H of 2028 - TipRanks
Buy Rating Affirmed for CG Oncology: Promising Advancements and Market Potential of Cretostimogene - TipRanks
CG Oncology price target lowered to $60 from $62 at BofA - TipRanks
CG Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Why CG Oncology, Inc. Stocks Are Rising - TipRanks
CG Oncology reports Q3 EPS (57c), consensus (55c) - TipRanks
CG Oncology Q3 Net Loss Widens; Revenue Rises - MarketScreener
Earnings Flash (CGON) CG Oncology, Inc. Reports Q3 Revenue $1.7M - MarketScreener
Earnings Flash (CGON) CG Oncology Posts Q3 Net Loss $0.57 a Share, vs. FactSet Est of $0.57 Loss - MarketScreener
CG Oncology Initiates Rolling BLA Submission for Cretostimogene Monotherapy in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Quiver Quantitative
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):